F. Hoffmann-La Roche AG
F. Hoffmann-La Roche simplifies its data infrastructure with AVEVA CONNECT
F. Hoffmann-La Roche, one of the world's largest pharmaceutical companies, treats millions of patients every year and tests billions of people with its diagnostic products. However, the group needed to make relevant data accessible to its specialized analysts to optimize drug development and diagnostics, simplify a complex server landscape and structure large amounts of unorganized information in its data lake. In partnership with AVEVA and Capgemini, Roche deployed AVEVA CONNECT, AVEVA PI System, AVEVA PI Data Infrastructure, AVEVA Advanced Analytics, AVEVA PI Vision and AVEVA PI Server to build a reliable cloud-based data platform. The solution efficiently aggregates and contextualizes data from numerous on-premises systems. The benefits are significant: end-to-end data availability, the possibility of eliminating up to 70 servers from the overall system landscape, and opportunities to improve asset reliability identified through early anomaly detection with advanced analytics.
Integrated AVEVA software
AVEVA CONNECT
F. Hoffmann-La Roche AG uses AVEVA CONNECT with Advanced Analytics to optimize its pharmaceutical operations. This cloud-based platform enables AI to be leveraged to improve the quality and efficiency of drug production.
Find out more
AVEVA PI System
Roche relies on AVEVA PI System with PI Vision and PI Server to oversee its biopharmaceutical production facilities. This platform ensures FDA compliance and optimization of manufacturing processes.
Find out more
FAQ
How does AVEVA CONNECT simplify pharmaceutical data infrastructure?
F. Hoffmann-La Roche, one of the world's largest pharmaceutical companies, faced a complex server landscape to aggregate its global data. AVEVA CONNECT, combined with AVEVA PI System, PI Data Infrastructure, PI Vision and PI Server, simplifies this architecture by consolidating sources in the cloud. The group could potentially eliminate up to 70 servers from its overall system landscape, reducing IT operating costs and freeing teams for higher-value projects in drug development and diagnostics.
How can pharmaceutical data be made usable for analysts?
Roche treats millions of patients and tests billions of people every year. To optimize drug development and diagnostics, analysts need relevant, contextualized data. AVEVA PI System and PI Data Infrastructure aggregate and organize data from the many on-site systems, while AVEVA PI Vision presents it in actionable dashboards. This end-to-end availability turns an initially unstructured data lake into a source of scientific and industrial value.
What role does AVEVA Advanced Analytics play in pharmaceutical equipment reliability?
AVEVA Advanced Analytics continuously analyzes Roche's AVEVA PI System data to detect anomalies early on pharmaceutical production and diagnostics equipment. These weak signals make it possible to identify opportunities to improve asset reliability before a failure affects production. In a sector where a manufacturing disruption can directly affect millions of patients, early detection is a major issue for continuity of supply and product quality.
Why deploy a cloud platform in the life sciences?
The pharmaceutical sector handles considerable volumes of data spread across many production sites and laboratories. AVEVA CONNECT gives Roche a reliable cloud platform that aggregates, secures and contextualizes this data globally. This approach reduces IT complexity (up to 70 fewer servers), improves data availability for analysts and encourages cross-functional analyses. It is a key step in the digital transformation of major pharmaceutical groups.
How can a pharmaceutical data management project succeed with an integration partner?
Roche carried out this project in partnership with AVEVA and Capgemini, combining the vendor's expertise (AVEVA CONNECT, PI System, PI Data Infrastructure, Advanced Analytics, PI Vision, PI Server) with Capgemini's integration capabilities. This collaboration aligns technical architecture, business processes and data governance. For major pharmaceutical companies, a project of this scale requires a multi-party approach: a leading vendor, a global integrator and internal business teams, which together ensure long-term success and adoption.